Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Safety of External Electrocardioversion in Device Patients (SEED)

3. november 2017 opdateret af: Universitätsklinikum Köln

Safety of External Electrocardioversion in Device Patients - the SEED Registry

Arrhythmias of the atria of the heart are a common comorbidity in patients with cardiac rhythm management devices, such as pacemakers and implantable cardioverter/defibrillators (ICD). External electrical cardioversion is an established method to achieve rhythm control (restore normal sinus rhythm) in patients with atrial arrhythmia. Little data on safety and efficacy of external electrical cardioversion in patients with cardiac rhythm management devices exists. Thus, available data on the safety of external electrical cardioversion in cardiac rhythm management patients lacks statistical power to accurately reflect the true hazard of external electrical cardioversion in patients with cardiac rhythm management devices.

The aim is to systematically include and follow all patients with cardiac rhythm management devices presenting for external electrical cardioversion, to analyse the effects of external electrical cardioversion on leads and devices.

Studieoversigt

Status

Ukendt

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Introduction Atrial arrhythmias are a common comorbidity in patients with cardiac rhythm management (CRM) devices, such as pacemakers and ICD. External electrical cardioversion is an established method to achieve rhythm control in patients with atrial arrhythmia. A paucity of data on safety and efficacy of external electrical cardioversion in patients with cardiac rhythm management devices exists. Most publications are of older date and predominantly case reports or case collections. Few prospective studies with a population of cardiac rhythm management patients after external electrical cardioversion have been published in recent years.

Thus, available data on the safety of external electrical cardioversion in cardiac rhythm management patients lacks statistical power to accurately reflect the true hazard of external electrical cardioversion in patients with cardiac rhythm management devices.

Rationale Electrocardioversion in Propofol sedation for atrial or ventricular tachyarrhythmia is an established therapy. It is routinely used for patients with cardiac rhythm management devices and the risk of device and lead affectation is deemed to be low. This assumption is currently not supported by substantial and current scientific data, mostly relying on older reports. No large, prospective trials with a population of patients with modern cardiac rhythm management devices exists.

Aim of the study The aim is to systematically include and follow all patients with cardiac rhythm management devices presenting for external electrical cardioversion, to analyse the effects of external electrical cardioversion on leads and devices. Thereby, providing reliable evidence and detecting possible SAE with a low incidence. Furthermore, to gather information on efficacy and recurrence rate in this population, to examine the value of external electrical cardioversion for rhythm control in these patients.

Undersøgelsestype

Observationel

Tilmelding (Forventet)

300

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Cologne, Tyskland, 50937
        • Rekruttering
        • University Hospital Cologne
        • Kontakt:
        • Ledende efterforsker:
          • Jakob Lüker, Dr.

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 99 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

All patients with implanted cardiac rhythm devices (pacemakers, ICD and CRT)

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years
  • Informed, written consent
  • Atrial or ventricular arrhythmia with indication for CV
  • Status post CRM implantation, including CRT-D

Exclusion Criteria:

  • Age < 18 years
  • Patients under guardianship or with mental disorders / disabilities
  • lead implantation < 4 weeks prior to CV
  • contraindications for eCV or transoesophageal echocardiographie (TOE)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: Kohorte
  • Tidsperspektiver: Fremadrettet

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Pacemaker patients
Patients with pacemaker, presenting for cardioversion.
ICD patients
Patients with ICD, presenting for cardioversion.
CRT patients
Patients with CRT device, presenting for cardioversion.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Composite safety endpoint: Changes of lead and device parameters
Tidsramme: 2 weeks after CV

assessed by device interrogation, if any of the following criteria is met:

  • a rise in threshold (at constant pulse duration) of >1V
  • exit block of any of the pacing leads
  • loss of programming of the device
  • rise in shock impedance by 50%
  • rise in charge time by 50%
  • drop in battery voltage of ≥0.2V within < 6 weeks
2 weeks after CV

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Efficacy Endpoint
Tidsramme: within 15 minutes after CV

Assessed by device interrogation and 12-lead ECG:

- restoration of normal sinus rhythm after CV

within 15 minutes after CV
Late changes of lead parameters
Tidsramme: 2 weeks after CV

Any of the below, assessed by device interrogation:

  • Lead impedance > 1000 Ohm
  • a rise in lead impedance by 50%
  • ventricular lead sensing < 2mV
  • atrial lead sensing < 1mV
2 weeks after CV
Inadvertent induction of ventricular fibrillation
Tidsramme: 10 seconds after CV
Assessed by 3 lead monitoring ECG
10 seconds after CV
Composite endpoint: Early lead changes
Tidsramme: within 15 minutes after CV

assessed by device interrogation, if any of the following criteria is met:

  • a rise in threshold (at constant pulse duration) of >1V
  • exit block of any of the pacing leads
  • Lead impedance > 1000 Ohm
  • a rise in lead impedance by 50%
  • ventricular lead sensing < 2mV
  • atrial lead sensing < 1mV
within 15 minutes after CV
Loss of programming
Tidsramme: within 15 minutes after CV

assessed by device interrogation:

- loss of programming of the device

within 15 minutes after CV
Change of shock impedance
Tidsramme: within 15 minutes after CV

assessed by device interrogation:

- rise in shock impedance by 50%

within 15 minutes after CV
Change of charge time
Tidsramme: within 15 minutes after CV

assessed by device interrogation:

- rise in charge time by 50%

within 15 minutes after CV

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Jakob Lüker, Dr., University Hospital Cologne
  • Studieleder: Daniel Steven, Prof. Dr., University Hospital Cologne

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. september 2014

Primær færdiggørelse (Forventet)

1. november 2018

Studieafslutning (Forventet)

1. december 2018

Datoer for studieregistrering

Først indsendt

5. september 2014

Først indsendt, der opfyldte QC-kriterier

16. september 2014

Først opslået (Skøn)

19. september 2014

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2017

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2017

Sidst verificeret

1. november 2017

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • UKK-SEED-2014

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner